Recommended Scope for NPS Testing in the United States

NPS SCOPE

Q4 2023

PURPOSE: The objective of this report is to provide updated guidance in developing an appropriate analytical scope of testing for novel psychoactive substances (NPS) in the United States (and around the world) based on current trends and intelligence. This report is based on information available in Q3 2023 and early Q4 2023 and is subject to change along with the drug market.

SUMMARY: The NPS landscape is changing rapidly, requiring laboratories to constantly remain abreast of new and emerging drugs locally, nationally, and internationally. To meet individualized needs, laboratories amend existing methods or develop new ones for detection and confirmation of NPS. This can be challenging for scientists as information about NPS detections can be regionalized and/or out-of-date, making it difficult to determine which drugs should be prioritized at a given time. **CFSRE**'s **NPS Discovery** and the **SOFT NPS Committee** have established the below recommendations for NPS scope based on information from extensive collaborations, partnerships, and initiatives which yield national and international perspectives. Suggested cut-off concentrations or reporting limits (in ng/mL) are listed for each NPS. These values are categorized (i.e., <1, 1-10, and >10 ng/mL) and determined based on currently available quantitative data and/or comparison to structurally similar NPS within the given sub-class.

BENZODIAZEPINES		OPIOIDS		STIMULANTS & HALLUCINOGENS		SYNTHETIC CANNABINOIDS	
TIER ONE (STRONGLY RECOMMEND)							
Bromazolam	1-10	Metonitazene	<]	N,N-Dimethylpentylone	>10	MDMB-4en-PINACA	<]
Desalkylgidazepam†	1-10	N-Pyrrolidino Protonitazene	<]	Pentylone	>10	ADB-BINACA (-BUTINACA)	<1
Flubromazepam	1-10	Protonitazene	<]	alpha-PiHP / alpha-PHP	>10	MDMB-BINACA (-BUTINACA)	<]
Etizolam [†]	1-10	N-Pyrrolidino Metonitazene	<1	2F-2-oxo-PCE / Fluorexetamine	1-10	ADB-5'Br-BINACA	<]
Flualprazolam	1-10	o/m/p-Fluorofentanyl	1-10	Eutylone	>10	*MDMB-PICA	<]
TIER TWO (RECOMMEND)							
Clonazolam‡	<7	Carfentanil	<7	N-Propyl Butylone	>10	CHO-4'Me-5'Br-FUBOXPYRA	<1
8-Aminoclonazolam‡	1-10	N-Desethyl Isotonitazene	<]	*2/3/4-Methylmethcathinone	1-10	ADB-4en-PINACA	<]
Desalkylflurazepam†	1-10	Isotonitazene	<]	^ 2C-B	<]	*NMDMSB	<]
*Pyrazolam	1-10	N-Pyrrolidino Etonitazene	<]	N-Cyclohexyl Butylone	>10	ADB-5'Br-PINACA	<7
TIER THREE (CONSIDER)							
^Rilmazafone ► Rilmazolam	1-10	Brorphine	<]	*N-Cyclohexyl Methylone	>10	*CH-PIATA	<7
Flubromazolam	1-10	Etodesnitazene	1-10	*2F-Deschloroketamine	<1	*ADB-FUBIATA	<]
4'Cl-Deschloroalprazolam	1-10	*Dipyanone	1-10	3-MeO-PCP / 4-MeO-PCP	<]	5F-MDMB-PICA	<]
*Deschloroetizolam	1-10	N-Piperidinyl Etonitazene	<]	MDPHP	>10	4F-MDMB-BINACA	<]

note. This may not be an an-inclusive list. Laboratories should consider additional times for inclusion for exclusion) based on local, national, anator international trends.



by the Society of Forensic Toxicologists (SOFI) NFS Committee in collaboration with the Center for Forensic Science Research and Education (CFSIEs) at the Fredic Redeets Family Foundation. This report was prepared by Aeer Kordulski, Onnan Papsun, Dani Mats, Kayla Elledere, Illias Shoff, Szabolcs Sofalvi, Svante Wikingson, Michael Truver, Cella Modell, Lana Goodon, and Barry Logan. The authors would like to acknowledge scientists and staff at our laboratories for their related movelements and contributions.

Discisiment The recommendations in this report are subject to chan with time as new information becomes available. Toxicologists shot consider that NDS may appear due to various pharmaceutical pricing.

Panding CFSREs NFS Discovery is funded in part by the Nations institute of Justice, Office of Justice Programs, U.S. Department of Justice (Award Number SPN)122+CC-0443-4-MIMU, "Implementation of NFS Discovery An Early Warning System for Noted Urgin Intelligence Surveillance, Monitoring, Response, and Forecasting using Drug Materials and Tockloody Populations in the UST? The opinions, findings conclusions and/or recommendations expressed in this publication are mostline or notification of the UST Description of Surveillance position of notification of the UST Description of Surveillance position or notification of the UST Description of Surveillance of Surveillance Surveillance of the UST Description of Surveillance of Surveillance Surveillance of the UST Description of Surveillance Surveilla

Suggested Citation: Krotulski et al. (2023) Recommended Scope fo NPS Testing in the United States Q4 2023, Center for Forensic Science Research and Education United States.